Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix enters into collaboration

Abstract:
‘SonoDrugs' consortium will develop new nanoparticulate drug carriers that can be activated for localized drug release using focused ultrasound

"This collaboration focuses on developing drug delivery nanocarriers

to enable novel, localized therapeutics for both cardiovascular diseases and cancer. Local drug delivery is expected to be triggered noninvasively using focused ultrasound under MRI guidance, which is intended

to be more patient-friendly, since side effects caused by conventional systemic dosage can, theoretically, be reduced."

Laurent Lévy, Ph.D., CEO, Nanobiotix

Nanobiotix enters into collaboration

PARIS, France | Posted on January 29th, 2009

Nanobiotix, an emerging nanomedicine company, announced today that it will collaborate with, among others, Philips, Erasmus University Medical Center (The Netherlands), the University of Münster (Germany) and the University of London in a four-year project known as ‘SonoDrugs' — which aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cardiovascular disease and cancer, the first- and second-leading causes, respectively, of death in the European Union (EU).

The SonoDrugs project includes a total of 15 industry partners, university medical centers, and academic institutions from throughout the EU and has a budget of $19 million (15.9 million Euros).

"We intend that the side effects of chemotherapeutic drugs and those for cardiovascular disease will be diminished, since targeted delivery will significantly alter biodistribution and also will lower the amount of drugs that are needed for treatment," said Laurent Lévy, Ph.D., President and CEO of Nanobiotix and Co-President of the French Technology Platform on Nanotechnology (FTPN). "By improving such techniques with triggered release from nanocarriers under image control by MRI and ultrasound, SonoDrugs is expected to set the stage for more reliable diagnosis and therapy. We expect to have our first nanocarriers developed within nine months, and we further expect to have developed our first drug-loaded nanocarriers within 15 months."

"For Nanobiotix, collaboration with SonoDrugs valorizes the Company's know-how in MRI contrast agents and activated therapies as well as nanoparticle design and manufacturing," said Dr. Lévy. "Furthermore, the number of applications and associated markets for Nanobiotix products will be increased by this collaboration. We are extremely pleased to be a part of this groundbreaking effort to enhance treatment of cancer and cardiovascular disease."

"The development of new materials and methodologies for image-guided drug delivery will require the combined strengths of multiple disciplines," said Simone Vulto, Ph.D., senior scientist at Philips Research and coordinator of the SonoDrugs project. "In the SonoDrugs project we are confident that we have brought together the necessary expertise to make a real contribution to improving the treatment of two of the world's killer diseases."

The SonoDrugs collaboration aims to develop new materials and drug nanocarrier systems for improved localized drug delivery that can be activated by ultrasound waves. MRI and ultrasound will be used to visualize and guide the drug-delivery process and also to provide immediate feedback on the success of the procedure, enabling adjustment and fine-tuning of the therapeutic intervention. This novel approach to localized drug delivery requires close collaboration of material science, clinical imaging and pharmaceutical technology, which is expected to lead to new scientific capabilities, medical products and therapy solutions for cardiovascular disease and cancer.

The 15 collaborators of the "SonoDrugs" consortium include: Nanobiotix; Philips Research Europe (Eindhoven); Philips Research Hamburg (Germany); Erasmus University Medical Center (the Netherlands); Lipoid AG (Switzerland); Univ. of Münster (Germany); Univ. of Cyprus; Ghent Univ. (Belgium); Univ. of Helsinki (Finland); Univ. of London; Technical Univ. of Eindhoven (the Netherlands); Univ. Tours-INSERM (France); Univ. Victor Segalen Bordeaux (France); Philips Medical Systems MR (Finland); and, Univ. of Udine (Italy).

####

About Nanobiotix
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™— a technology platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy’s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance—not a drug—that can be activated to locally (intratumor) increase the dose of Xray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

For more information, please click here

Contacts:
Ronald Trahan
Phone: 508-359-4005, x108

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanosensors could help determine tumors’ ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Cambrios at CEATEC - Japan 2016 September 29th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

Nanomedicine

Nanosensors could help determine tumors’ ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Announcements

Nanosensors could help determine tumors’ ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Cambrios at CEATEC - Japan 2016 September 29th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

Alliances/Trade associations/Partnerships/Distributorships

PHENOMEN is a FET-Open Research Project aiming to lay the foundations a new information technology September 19th, 2016

SEMI and MSIG Join Together in Strategic Association Partnership: MEMS & Sensors Industry Group Brings New MEMS and Sensors Community to SEMI to Increase Combined Member Value September 15th, 2016

Leti and Oberthur Technologies Partner to Explore New Solutions in Fast-growing Digital Era September 12th, 2016

Synopsys Joins GLOBALFOUNDRIES’ FDXcelerator Partner Program to Enable Innovative Designs Using the FD-SOI Process: Program Gives Synopsys Access to GLOBALFOUNDRIES’ FDX Portfolio and Provides Customers with Tools that Support the Differentiated Features of FD-SOI September 8th, 2016

Research partnerships

Crystalline Fault Lines Provide Pathway for Solar Cell Current: New tomographic AFM imaging technique reveals that microstructural defects, generally thought to be detrimental, actually improve conductivity in cadmium telluride solar cells September 26th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic